161 related articles for article (PubMed ID: 24375252)
1. The co-expression of telomerase and ALT pathway in human breast cancer tissues.
Xu B; Peng M; Song Q
Tumour Biol; 2014 May; 35(5):4087-93. PubMed ID: 24375252
[TBL] [Abstract][Full Text] [Related]
2. Telomere maintenance by telomerase and by recombination can coexist in human cells.
Cerone MA; Londono-Vallejo JA; Bacchetti S
Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
[TBL] [Abstract][Full Text] [Related]
3. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
Grobelny JV; Kulp-McEliece M; Broccoli D
Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
[TBL] [Abstract][Full Text] [Related]
4. PML and TRF2 protein expression in hereditary and sporadic colon cancer.
Plevová P; Bouchal J; Fiurásková M; Papezová M; Krepelová A; Curík R; Foretová L; Navrátilová M; Zapletalová J; Posolda T; Kolár Z
Neoplasma; 2007; 54(4):269-77. PubMed ID: 17822315
[TBL] [Abstract][Full Text] [Related]
5. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells.
Perrem K; Colgin LM; Neumann AA; Yeager TR; Reddel RR
Mol Cell Biol; 2001 Jun; 21(12):3862-75. PubMed ID: 11359895
[TBL] [Abstract][Full Text] [Related]
6. Telomerase suppression initiates PML-dependent p53 activation to inhibit bladder cancer cell growth.
Xue Y; Li L; Zhang D; Wu K; Guo P; Zeng J; Wang X; He D
Oncol Rep; 2010 Dec; 24(6):1551-9. PubMed ID: 21042751
[TBL] [Abstract][Full Text] [Related]
7. The alternative lengthening of telomeres pathway may operate in non-neoplastic human cells.
Slatter TL; Tan X; Yuen YC; Gunningham S; Ma SS; Daly E; Packer S; Devenish C; Royds JA; Hung NA
J Pathol; 2012 Feb; 226(3):509-18. PubMed ID: 22250043
[TBL] [Abstract][Full Text] [Related]
8. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.
Draskovic I; Arnoult N; Steiner V; Bacchetti S; Lomonte P; Londoño-Vallejo A
Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15726-31. PubMed ID: 19717459
[TBL] [Abstract][Full Text] [Related]
9. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle.
Grobelny JV; Godwin AK; Broccoli D
J Cell Sci; 2000 Dec; 113 Pt 24():4577-85. PubMed ID: 11082050
[TBL] [Abstract][Full Text] [Related]
10. Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT.
Brachner A; Sasgary S; Pirker C; Rodgarkia C; Mikula M; Mikulits W; Bergmeister H; Setinek U; Wieser M; Chin SF; Caldas C; Micksche M; Cerni C; Berger W
Cancer Res; 2006 Apr; 66(7):3584-92. PubMed ID: 16585183
[TBL] [Abstract][Full Text] [Related]
11. Alternative lengthening of telomeres in hTERT-inhibited laryngeal cancer cells.
Chen W; Xiao BK; Liu JP; Chen SM; Tao ZZ
Cancer Sci; 2010 Aug; 101(8):1769-76. PubMed ID: 20545697
[TBL] [Abstract][Full Text] [Related]
12. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body.
Yeager TR; Neumann AA; Englezou A; Huschtscha LI; Noble JR; Reddel RR
Cancer Res; 1999 Sep; 59(17):4175-9. PubMed ID: 10485449
[TBL] [Abstract][Full Text] [Related]
13. PML induces compaction, TRF2 depletion and DNA damage signaling at telomeres and promotes their alternative lengthening.
Osterwald S; Deeg KI; Chung I; Parisotto D; Wörz S; Rohr K; Erfle H; Rippe K
J Cell Sci; 2015 May; 128(10):1887-900. PubMed ID: 25908860
[TBL] [Abstract][Full Text] [Related]
14. Stable expression of promyelocytic leukaemia (PML) protein in telomerase positive MCF7 cells results in alternative lengthening of telomeres phenotype.
Yong JW; Yeo X; Khan MM; Lee MB; Hande MP
Genome Integr; 2012 Aug; 3(1):5. PubMed ID: 22925423
[TBL] [Abstract][Full Text] [Related]
15. PML is required for telomere stability in non-neoplastic human cells.
Marchesini M; Matocci R; Tasselli L; Cambiaghi V; Orleth A; Furia L; Marinelli C; Lombardi S; Sammarelli G; Aversa F; Minucci S; Faretta M; Pelicci PG; Grignani F
Oncogene; 2016 Apr; 35(14):1811-21. PubMed ID: 26119943
[TBL] [Abstract][Full Text] [Related]
16. Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres.
Slatter T; Gifford-Garner J; Wiles A; Tan X; Chen YJ; MacFarlane M; Sullivan M; Royds J; Hung N
Am J Pathol; 2010 Dec; 177(6):2694-700. PubMed ID: 21037079
[TBL] [Abstract][Full Text] [Related]
17. Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R.
Fujiwara M; Kamma H; Wu W; Yano Y; Homma S; Satoh H
Int J Oncol; 2006 Aug; 29(2):445-51. PubMed ID: 16820888
[TBL] [Abstract][Full Text] [Related]
18. PML-IV functions as a negative regulator of telomerase by interacting with TERT.
Oh W; Ghim J; Lee EW; Yang MR; Kim ET; Ahn JH; Song J
J Cell Sci; 2009 Aug; 122(Pt 15):2613-22. PubMed ID: 19567472
[TBL] [Abstract][Full Text] [Related]
19. Telomere biology in giant cell tumour of bone.
Forsyth RG; De Boeck G; Bekaert S; De Meyer T; Taminiau AH; Uyttendaele D; Roels H; Praet MM; Hogendoorn PC
J Pathol; 2008 Apr; 214(5):555-63. PubMed ID: 18278785
[TBL] [Abstract][Full Text] [Related]
20. Augmented telomerase activity, reduced telomere length and the presence of alternative lengthening of telomere in renal cell carcinoma: plausible predictive and diagnostic markers.
Pal D; Sharma U; Khajuria R; Singh SK; Kakkar N; Prasad R
Gene; 2015 May; 562(2):145-51. PubMed ID: 25769384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
